Could Statin Use Be Associated with Reduced Recurrence Rates following Coiling in Ruptured Intracranial Aneurysms?

References

1. 1.↵
   2. Ferns SP,
   3. Sprengers ME,
   4. van Rooij WJ, et al

   . Coiling of intracranial aneurysms: a systematic review on initial occlusion and reopening and retreatment rates. Stroke 2009;40:e523–529 doi:10.1161/STROKEAHA.109.553099 pmid:19520984

   Abstract/FREE Full Text
2. 2.↵
   2. Landmesser U,
   3. Engberding N,
   4. Bahlmann FH, et al

   . Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933–39 doi:10.1161/01.CIR.0000143232.67642.7A pmid:15466656

   Abstract/FREE Full Text
3. 3.↵
   2. Song L,
   3. Yang YJ,
   4. Dong QT, et al

   . Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase. PLoS One 2013;8:e65702 doi:10.1371/journal.pone.0065702 pmid:23741509

   CrossRefPubMed
4. 4.↵
   2. Sonobe M,
   3. Hattori K,
   4. Tomita N, et al

   . Stimulatory effects of statins on bone marrow-derived mesenchymal stem cells: study of a new therapeutic agent for fracture. Biomed Mater Eng 2005;15:261–67 pmid:16010034

   PubMed
5. 5.↵
   2. Brinjikji W,
   3. Kallmes DF,
   4. Kadirvel R

   . Mechanisms of healing in coiled intracranial aneurysms: a review of the literature. AJNR Am J Neuroradiol 2015;36:1216–22 doi:10.3174/ajnr.A4175 pmid:25430855

   Abstract/FREE Full Text
6. 6.↵
   2. Blanco-Colio LM,
   3. Tuñón J,
   4. Martin-Ventura JL, et al

   . Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003;63:12–23 doi:10.1046/j.1523-1755.2003.00744.x pmid:12472764

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Bouzeghrane F,
   3. Darsaut T,
   4. Salazkin I, et al

   . Matrix metalloproteinase-9 may play a role in recanalization and recurrence after therapeutic embolization of aneurysms or arteries. J Vasc Interv Radiol 2007;18:1271–79 doi:10.1016/j.jvir.2007.06.034 pmid:17911518

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Marchese E,
   3. Vignati A,
   4. Albanese A, et al

   . Comparative evaluation of genome-wide gene expression profiles in ruptured and unruptured human intracranial aneurysms. J Biol Regul Homeost Agents 2010;24:185–95 pmid:20487632

   PubMed
9. 9.↵
   2. Serra R,
   3. Volpentesta G,
   4. Gallelli L, et al

   . Metalloproteinase-9 and neutrophil gelatinase-associated lipocalin plasma and tissue levels evaluation in middle cerebral artery aneurysms. Br J Neurosurg 2014 May 5. [Epub ahead of print] doi:10.3109/02688697.2014.913777 pmid:24799278

   CrossRefPubMed
10. 10.↵
    2. Jin D,
    3. Sheng J,
    4. Yang X, et al

    . Matrix metalloproteinases and tissue inhibitors of metalloproteinases expression in human cerebral ruptured and unruptured aneurysm. Surg Neurol 2007;68(suppl 2):S11–16; discussion S16 doi:10.1016/j.surneu.2007.02.060 pmid:17714769

    CrossRefPubMed
11. 11.↵
    2. Kim SC,
    3. Singh M,
    4. Huang J, et al

    . Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 1997;41:642–46; discussion 646–47 pmid:9310982

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Razavian M,
    3. Zhang J,
    4. Nie L, et al

    . Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. J Nucl Med 2010;51:1107–15 doi:10.2967/jnumed.110.075259 pmid:20554725

    Abstract/FREE Full Text
13. 13.↵
    2. Aoki T,
    3. Kataoka H,
    4. Morimoto M, et al

    . Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke 2007;38:162–69 doi:10.1161/01.STR.0000252129.18605.c8 pmid:17122420

    Abstract/FREE Full Text
14. 14.↵
    2. Pannu H,
    3. Kim DH,
    4. Guo D, et al

    . The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg 2006;105:418–23 doi:10.3171/jns.2006.105.3.418 pmid:16961137

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Bellosta S,
    3. Via D,
    4. Canavesi M, et al

    . HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671–78 doi:10.1161/01.ATV.18.11.1671 pmid:9812903

    Abstract/FREE Full Text
16. 16.↵
    2. Ganné F,
    3. Vasse M,
    4. Beaudeux JL, et al

    . Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes: a possible protective mechanism against atherothrombosis. Thromb Haemost 2000;84:680–88 pmid:11057870

    PubMedWeb of Science
17. 17.↵
    2. Guo H,
    3. Shi Y,
    4. Liu L, et al

    . Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Arch Med Res 2009;40:345–51 doi:10.1016/j.arcmed.2009.07.006 pmid:19766896

    CrossRefPubMed
18. 18.↵
    2. Wong B,
    3. Lumma WC,
    4. Smith AM, et al

    . Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001;69:959–62 pmid:11404382

    Abstract/FREE Full Text
19. 19.↵
    2. Hasan DM,
    3. Nadareyshvili AI,
    4. Hoppe AL, et al

    . Cerebral aneurysm sac growth as the etiology of recurrence after successful coil embolization. Stroke 2012;43:866–68 doi:10.1161/STROKEAHA.111.637827 pmid:22180247

    Abstract/FREE Full Text
20. 20.↵
    2. Luan Z,
    3. Chase AJ,
    4. Newby AC

    . Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769–75 doi:10.1161/01.ATV.0000068646.76823.AE pmid:12663370

    Abstract/FREE Full Text
21. 21.↵
    2. Nyan M,
    3. Miyahara T,
    4. Noritake K, et al

    . Molecular and tissue responses in the healing of rat calvarial defects after local application of simvastatin combined with alpha tricalcium phosphate. J Biomed Mater Res B Appl Biomater 2010;93:65–73 doi:10.1002/jbm.b.31559 pmid:20024970

    CrossRefPubMed
22. 22.↵
    2. Kodama T,
    3. Iwata H

    . Comparison of bare metal and statin-coated coils on rates of intra-aneurysmal tissue organization in a rat model of aneurysm. J Biomed Mater Res B Appl Biomater 2013;101:656–62 doi:10.1002/jbm.b.32869 pmid:23359484

    CrossRefPubMed
23. 23.↵
    2. Raux M,
    3. Cochennec F,
    4. Becquemin JP

    . Statin therapy is associated with aneurysm sac regression after endovascular aortic repair. J Vasc Surg 2012;55:1587–92 doi:10.1016/j.jvs.2011.12.040 pmid:22459742

    CrossRefPubMed
24. 24.↵
    2. Gray C,
    3. Goodman P,
    4. O'Malley MK, et al

    . Statins promote residual aneurysm sac regression following endovascular aortic aneurysm repair. Vasc Endovasc Surg 2014;48:111–15 doi:10.1177/1538574413513846 pmid:24347280

    Abstract/FREE Full Text
25. 25.↵
    2. Chalouhi N,
    3. Tjoumakaris S,
    4. Gonzalez LF, et al

    . Coiling of large and giant aneurysms: complications and long-term results of 334 cases. AJNR Am J Neuroradiol 2014;35:546–52 doi:10.3174/ajnr.A3696 pmid:23945229

    Abstract/FREE Full Text
26. 26.↵
    2. Crobeddu E,
    3. Lanzino G,
    4. Kallmes DF, et al

    . Review of 2 decades of aneurysm-recurrence literature, part 1: reducing recurrence after endovascular coiling. AJNR Am J Neuroradiol 2013;34:266–70 doi:10.3174/ajnr.A3032 pmid:22422180

    Abstract/FREE Full Text